JP2017510627A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510627A5
JP2017510627A5 JP2016574516A JP2016574516A JP2017510627A5 JP 2017510627 A5 JP2017510627 A5 JP 2017510627A5 JP 2016574516 A JP2016574516 A JP 2016574516A JP 2016574516 A JP2016574516 A JP 2016574516A JP 2017510627 A5 JP2017510627 A5 JP 2017510627A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antagonist
mcam
composition according
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016574516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510627A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/051785 external-priority patent/WO2015136468A1/en
Publication of JP2017510627A publication Critical patent/JP2017510627A/ja
Publication of JP2017510627A5 publication Critical patent/JP2017510627A5/ja
Pending legal-status Critical Current

Links

JP2016574516A 2014-03-13 2015-03-12 多発性硬化症の併用治療 Pending JP2017510627A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461952835P 2014-03-13 2014-03-13
US61/952,835 2014-03-13
US201462023577P 2014-07-11 2014-07-11
US62/023,577 2014-07-11
PCT/IB2015/051785 WO2015136468A1 (en) 2014-03-13 2015-03-12 Combination treatment for multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020019355A Division JP2020100631A (ja) 2014-03-13 2020-02-07 多発性硬化症の併用治療

Publications (2)

Publication Number Publication Date
JP2017510627A JP2017510627A (ja) 2017-04-13
JP2017510627A5 true JP2017510627A5 (enExample) 2018-04-19

Family

ID=52737375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016574516A Pending JP2017510627A (ja) 2014-03-13 2015-03-12 多発性硬化症の併用治療
JP2020019355A Pending JP2020100631A (ja) 2014-03-13 2020-02-07 多発性硬化症の併用治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020019355A Pending JP2020100631A (ja) 2014-03-13 2020-02-07 多発性硬化症の併用治療

Country Status (6)

Country Link
US (1) US20170002077A1 (enExample)
EP (1) EP3116910A1 (enExample)
JP (2) JP2017510627A (enExample)
KR (1) KR20170052526A (enExample)
CA (1) CA2938945A1 (enExample)
WO (1) WO2015136468A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
WO2017134178A1 (en) * 2016-02-05 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Imaging method for predicting the onset of multiple sclerosis
WO2017149513A1 (en) * 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
JP7306635B2 (ja) * 2017-11-09 2023-07-11 北海道公立大学法人 札幌医科大学 組織再生用医薬及びその製造方法
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ATE318841T1 (de) 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
PL338373A1 (en) 1997-07-31 2000-10-23 Elan Pharm Inc Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
IL133640A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
CN1265675A (zh) 1997-07-31 2000-09-06 伊兰药品公司 抑制由vla-4介导的白细胞粘着的苄基化合物
KR100554815B1 (ko) 1997-08-22 2006-02-22 에프. 호프만-라 로슈 아게 엔-아로일페닐알라닌 유도체
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
HUP0101419A3 (en) 1998-04-16 2002-08-28 Texas Biotechnology Corp Houst Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821406D0 (en) 1998-10-01 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
RU2263109C2 (ru) 1999-05-07 2005-10-27 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
AU6909300A (en) 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
AU2001278986A1 (en) 2000-07-21 2002-02-05 Elan Pharmaceuticals, Inc. 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
US7192931B2 (en) * 2000-10-12 2007-03-20 Neuren Pharmaceuticals Ltd. Treatment of demyelinating diseases
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7361679B2 (en) 2001-09-12 2008-04-22 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
JP2007521249A (ja) * 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
CA2690382A1 (en) * 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
WO2012001647A2 (en) * 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2012170071A1 (en) 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法

Similar Documents

Publication Publication Date Title
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
HRP20241447T1 (hr) Bispecifična inhibitor antitijela kontrolnih točaka
HRP20190643T1 (hr) Protutijela protiv dkk-1
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
HRP20201729T1 (hr) Antitijela protiv aktivina a i njihova primjena
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
RU2018102798A (ru) Антитела к фактору xi и способы их применения
RU2018119686A (ru) Антитела и фрагменты антител для сайт-специфического конъюгирования
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2016536322A5 (enExample)
JP2014518883A5 (enExample)
PH12015501505B1 (en) Antibodies that bind to tl1a and their uses
JP2016029056A5 (enExample)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
RU2018132044A (ru) Антитела против тау
JP2016183153A5 (enExample)
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
JP2014534237A5 (enExample)
JP2014518898A5 (enExample)
HRP20220069T1 (hr) Antitijelo
JP2015509960A5 (enExample)
JP2014527396A5 (enExample)
JP2017511152A5 (enExample)
JP2014518198A5 (enExample)